Ocular Therapeutix is an integrated biopharmaceutical company that develops innovative therapies for retinal and ocular diseases based on its proprietary ELUTYX bioresorbable hydrogel platform, which enables local, programmed release of therapeutic agents directly to the eye and has been safely used in millions of patients across multiple FDA-approved treatments. The company generates revenue through direct U.S. commercialization of DEXTENZA, an FDA-approved drug-eluting insert for ocular inflammation, pain, and itching, which it sells via specialty distributors and direct channels supported by payer arrangements, while also collecting upfront and milestone payments plus royalties from a license agreement with AffaMed Therapeutics for Asian territories. The company's pipeline includes AXPAXLI, an investigational axitinib intravitreal hydrogel in Phase 3 development for wet age-related macular degeneration and diabetic retinal disease, and OTX-TIC, a travoprost intracameral hydrogel candidate for glaucoma treatment, with manufacturing and commercialization supported by its cGMP facility in Massachusetts.